Tero-Pekka Alastalo - Spin-Offs to Exit | Heart Health | US Expansion

On this epsiode we are hosting Tero-Pekka Alastalo. Tero and his team founded BluePrint Genetics a Stanford University spin off that has been focusing on developing innovative technologies for rare disease genetic diagnostics. The company was acquired by Quest Diagnostics in 2020.  Together we are talking about the early stages of building Blueprint Genetics and the aspects of expanding companies in the US market.  We also cover venture opportunities for heart health and talk about CardioSignal, which is developing a disruptive mobile application-based technology to improve the detection of heart disease.